When to Resume Eliquis After Lithotripsy
Resume Eliquis (apixaban) 24 hours after lithotripsy if it is a low bleeding risk procedure, or 48-72 hours after if there are concerns about hemostasis or higher bleeding risk.
Procedural Bleeding Risk Classification
Lithotripsy (extracorporeal shock wave lithotripsy, ESWL) is generally considered a low-to-moderate bleeding risk procedure based on urological guidelines 1. However, the specific type of lithotripsy matters:
- ESWL (shock wave lithotripsy): Lower bleeding risk
- Ureteroscopic lithotripsy: Can be performed with continued anticoagulation according to some evidence 2
- Percutaneous nephrolithotomy: Higher bleeding risk, requires longer interruption
Resumption Timing Based on Guidelines
For Standard ESWL (Low Bleeding Risk):
Resume apixaban 5 mg twice daily starting 24 hours after the procedure 3. The FDA label supports restarting "as soon as adequate hemostasis has been established" 4.
For Higher Risk Lithotripsy or Complicated Cases:
Resume apixaban 48-72 hours after the procedure 3, 5. The Canadian guidelines specifically recommend resuming DOACs "1 day after hemostasis is established (usually 48 hours for a procedure with low risk of bleeding and 72 hours for a procedure with an intermediate or high risk of bleeding)" 5.
Practical Algorithm for Resumption
Assess hemostasis at 24 hours post-procedure:
- No hematuria or minimal clearing hematuria → Resume at 24 hours
- Persistent significant hematuria → Delay to 48-72 hours
- Active bleeding or hematoma → Delay until resolved
Consider patient thrombotic risk:
- High thrombotic risk (CHADS₂ ≥3, recent stroke, mechanical valve): Consider reduced dose (2.5 mg twice daily) at 24 hours, then full dose at 48 hours 3
- Standard risk: Resume full dose (5 mg twice daily) at 24 hours
No bridging anticoagulation needed during the interruption period 6, 4
Key Clinical Considerations
Preoperative Management
The French guidelines recommend stopping apixaban 1-2 days before low hemorrhagic risk procedures 6. The FDA label states discontinuation should occur at least 24 hours prior to procedures with low bleeding risk 4.
Common Pitfalls to Avoid
- Do not bridge with heparin: The rapid onset of apixaban (peak effect in 3-4 hours) makes bridging unnecessary and increases bleeding risk 3, 6
- Do not resume too early: The 24-hour minimum allows for adequate wound hemostasis and reduces postoperative bleeding complications
- Do not use reduced doses routinely: Only consider dose reduction (2.5 mg twice daily) in high thrombotic risk patients during the first 2-3 days post-procedure 3
Special Populations
Renal impairment: Apixaban has only 25% renal clearance 3, so standard timing applies unless creatinine clearance is severely reduced (<15 mL/min)
Elderly or low body weight: If patient is already on 2.5 mg twice daily chronically, resume this dose at the same timing intervals
Evidence Quality Note
The guidelines are based on conditional recommendations with low-quality evidence 5, derived primarily from expert consensus and extrapolation from orthopedic surgery data rather than lithotripsy-specific trials. However, the consistent recommendations across multiple international guidelines (Blood, Canadian Cardiovascular Society, French GIHP) and FDA labeling provide a robust framework for clinical decision-making.